Cholangitis

An imbalance in the blood between long-chain and very long-chain ceramides — fatty molecules that help fine-tune the body’s inflammatory response — may help indicate…

About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…

The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).

Note: This story was updated Aug. 8, 2025, to correct that infectious mononucleosis was linked to a 4.6 times higher risk of future PSC, not  a…

A Phase 1b/2a clinical trial of golexanolone, Umecrine Cognition’s candidate therapy for cognitive symptoms and fatigue related to primary biliary cholangitis (PBC), will resume…

The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…

The global prevalence of primary sclerosing cholangitis (PSC), or the total number of existing cases, is expected to increase substantially over the next several…

Nearly six months of treatment with the experimental oral candidate linerixibat significantly reduced itch and itch-related sleep problems for adults with primary biliary cholangitis…

The efficacy of Livdelzi (seladelpar) at treating primary biliary cholangitis (PBC) is similar irrespective of whether patients previously received other medications, according to…

An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…